Geode Capital Management
IBO

Geode Capital Management’s Impact BioMedical IBO Stock Holding History

Geode Capital Management’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$716K Buy
1,192,925
+1,118,547
+1,504% +$559K ﹤0.01% 3464
2025
Q4 		$37.6K Buy
74,378
+29,269
+65% +$15.5K ﹤0.01% 4285
2025
Q3 		$30K Sell
45,109
-4,760
-10% -$3K ﹤0.01% 4381
2025
Q2 		$32.3K Buy
49,869
+26,669
+115% +$15K ﹤0.01% 4291
2025
Q1 		$20.2K Buy
23,200
+2,426
+12% +$4.2K ﹤0.01% 4343
2024
Q4 		$30.1K Buy
+20,774
New +$43.1K ﹤0.01% 4325

Other funds holding IBO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management's IBO Position: Q1 2026 in Review

Geode Capital Management increased its Impact BioMedical (IBO) stake by 1,504% in Q1 2026, buying an estimated $559K and bringing the position to 1,192,925 shares worth $716K. The position accounts for ﹤0.01% of the portfolio, ranked #3464.

Geode Capital Management first reported a position in IBO in Q4 2024 and has held it in 6 quarters since. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • Geode Capital Management held 1,192,925 shares of Impact BioMedical worth $716K as of Q1 2026.
  • Geode Capital Management bought 1,118,547 Impact BioMedical shares in Q1 2026, an estimated $559K.
  • Impact BioMedical made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3464 holding.
  • Geode Capital Management first reported a position in Impact BioMedical in Q4 2024 and has held it in 6 quarters since.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.